findmyKOL
Clinical trialNCT06796998RecruitingPhase 2Interventional

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

SponsorIzidore Lossos, MDEnrollment25Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueMarginal Zone LymphomaNodal Marginal Zone LymphomaSplenic Marginal Zone Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Miami

    Miami, Florida, United States

    Izidore Lossos, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
13 Oct 2025
Primary completion
15 Oct 2028
Completion
15 Apr 2031
Last update posted
28 Oct 2025
Registered enrollment
25
Registry id
NCT06796998
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.